Literature DB >> 10213217

Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis.

A Scorilas1, J Yotis, C Pateras, T Trangas, M Talieri.   

Abstract

The value of various prognostic factors in breast cancer patients has been determined in a number of studies. One hundred thirty-eight Greek women were followed up over a 5-year period after surgery for breast cancer. Amplification and overexpression of c-erbB-2 was found in 22.4% and 29.7% of the respective cases, and the concentration of total cytosolic Cathepsin-D (CD) in 46.4% of them was high (> or = 60 pmol/mg protein). The examined biological variables were compared with standard clinicopathological prognostic factors for the disease and related to early relapse (ER; before 3 years), relapse-free survival (RFS; median, 5 years), and overall survival (OS; median, 5 years). It was found that high CD levels significantly shorten ER of both node-negative and node-positive patients (P < 0.0001 and P = 0.002, respectively) and have prognostic value for RFS and OS of node-negative patients (P = 0.0012 and P = 0.0288, respectively), but lose their value as relapse predictors for node-positive patients for periods longer than 3 years. Overexpression of c-erbB-2 was found to be predictive for OS of node-positive and -negative patients (P = 0.0048 and P = 0.0285, respectively), but its predictive power was weak for ER (P = 0.0456) and RFS (P = 0.0455) of node-negative patients and disappeared for node-positive patients. c-erbB-2 amplification offers minimal assistance to the prediction. In conclusion, high CD concentration is indicative of ER of patients, and c-erbB-2 overexpression correlates with OS of patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10213217

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  7 in total

1.  HER2 Pro1170Ala polymorphism is associated with decreased survival rate in HER2-negative breast cancer.

Authors:  Pilei Si; Ye Xu; Tao Ouyang; Jinfeng Li; Tianfeng Wang; Zhaoqing Fan; Tie Fan; Benyao Lin; Yuntao Xie
Journal:  Oncol Lett       Date:  2017-03-17       Impact factor: 2.967

2.  Correlation between cathepsin D expression and p53 protein nuclear accumulation in oesophageal squamous cell carcinoma.

Authors:  M Ikeguchi; T Sakatani; T Ueta; K Fukuda; S Oka; K Hisamitsu; K Yamaguchi; S Tsujitani; N Kaibara
Journal:  J Clin Pathol       Date:  2002-02       Impact factor: 3.411

3.  The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer.

Authors:  G M Yousef; A Scorilas; A Magklara; N Memari; R Ponzone; P Sismondi; N Biglia; M Abd Ellatif; E P Diamandis
Journal:  Br J Cancer       Date:  2002-11-18       Impact factor: 7.640

4.  Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis.

Authors:  G M Yousef; C A Borgoño; A Scorilas; R Ponzone; N Biglia; L Iskander; M-E Polymeris; R Roagna; P Sismondi; E P Diamandis
Journal:  Br J Cancer       Date:  2002-11-18       Impact factor: 7.640

5.  Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients.

Authors:  A Scorilas; A Karameris; N Arnogiannaki; A Ardavanis; P Bassilopoulos; T Trangas; M Talieri
Journal:  Br J Cancer       Date:  2001-06-01       Impact factor: 7.640

6.  Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis.

Authors:  A Scorilas; T Trangas; J Yotis; C Pateras; M Talieri
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

7.  Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer.

Authors:  A Chang; G M Yousef; A Scorilas; L Grass; P Sismondi; R Ponzone; E P Diamandis
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.